top of page
Search

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

"Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX)."

Intervention / Treatment

  • Drug: KRAS Vaccine with Poly-ICLC adjuvant

  • Drug: Balstilimab

  • Drug: Botensilimab

 

Phase 2 trial at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 

to open September 2024

50 patients

 

NOTE: All interventional clinical trials involve risk. So please discuss the trial with your oncology team as well as ask questions of the trial researchers.

 

 



Genentech_Logo.png_dark blue text that reads, "Genetech." Gray italicized text that reads, "a member of the Roche Group."
Blue capitalized text on a gray background. Text reads, "Amgen."
Dark blue text on top of sea foam text. Text reads, "Verastem Oncology."
Black capitalized text that reads, "Revolution Medicine."
bottom of page